Clinical Study of Regulatory T Cells (Tregs) in the Treatment of Neurodegenerative Diseases

Novabio Therapeutics

Status and phase: Enrolling; Phase 1

Conditions: Amyotrophic Lateral Sclerosis (ALS)

Treatments: Biological: Autologous Human Polyclonal Regulatory T Cells Injection (NP001 Cell Injection)

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT06671236

NP001-NDD02

Details and patient eligibility

About

An open, multi- center phase Ⅰ clinical study evaluating the safety and efficacy of autologous human polyclonal regulatory T cell injection (NP001 cell injection) in patients with Neurodegenerative diseases (ALS).

Full description

This is an open-label, non-randomized, multi-center clinical trial of single-agent NP001 cell injection in patients with with Neurodegenerative diseases (ALS).

After subject consents to the study, an apheresis procedure will be performed to collect cells to manufacture the investigational product, NP001 cell injection. NP001 cell injection are manufactured ex vivo to yield enriched Tregs.

This study is evaluating NP001 cell injection at the dose of 1x E6 cells, 1x E7 cells, and 1x E8 cells/times, with up to 3 times separated by 4 weeks among dosing (intrathecally on Days 1, 29, and 57). Study subjects are then followed for several months to capture safety and efficacy parameters. The total duration of NP001 cell injection and follow-up interval on this protocol is approximately 12-months.

Enrollment: 12 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

-

Patients must meet all of the following criteria to be eligible for enrollment in this study:

1. Male or female patients aged 18 to 70 years;

2. According to current international diagnostic criteria:

   ALS: defined by the Gold Coast Diagnostic Criteria (Shefner, 2020) as having a diagnosis of sporadic or familial amyotrophic lateral sclerosis (ALS), diagnosed as a probable, probable, or definite patient with laboratory support according to the World Federation of Neurology El Escorial criteria;

3. If there is a stable dose for more than one month prior to study entry. For example, patients with ALS can continue treatment with riluzole (Rilutek®) and/or edaravone (Radicava®);

4. Patients must have > two weeks after the end of major surgery and after the completion of participation in other research trials;

5. Patients must have recovered from clinical toxicity (CTCAE [5th Edition] toxicity values have resolved to < 2);

6. Serum creatinine less than or equal to 2.0 mg/dL;

7. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x upper limit of normal;

8. Bilirubin < 1.5 (except Gilbert's disease);

9. Lung slow vital capacity (SVC) > 70% of predicted normal;

10. No history of abnormal bleeding tendency;

11. Informed consent must be obtained prior to performing any study-related procedures that are not part of standard medical care, with the understanding that the participant may withdraw from the study without influence for the future medical care.

Exclusion criteria

-

Subjects with any of the following cannot be enrolled in this study:

1. uncontrolled infection;
2. < 3 drugs do not adequately control hypertension;
3. Documented history of pulmonary embolism within 6 months of enrollment;
4. Clinically significant cardiology, defined as: myocardial infarction, NYHA-graded class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmia, or ECG evidence of acute ischemia or abnormal conduction system within 6 months prior to enrollment;
5. Patients with a history of coronary artery bypass grafting or angioplasty will be evaluated by cardiology and considered on a case-by-case basis;
6. Seropositive for HIV, hepatitis B or hepatitis C;
7. Pregnant or lactating patients;
8. Patients of childbearing potential or males with partners of childbearing potential who are unwilling to use contraception;
9. Participation in any other interventional study;
10. Treatment with another investigational drug, biologic, or device within 30 days or 5 half-lives (whichever is longer) of the screening period. Patient participation in observational/non-interventional clinical studies will be discussed with the Medical Monitor;
11. Prior treatment with ALS gene or cell therapy;
12. History of clinically significant tumor, liver or kidney disease, or other uncontrolled disease;
13. presence of a feeding tube;
14. Current use of antipsychotics, antiepileptic drugs (except benzodiazepines, gabapentin, pre-Bahrain) or class 1 (e.g., flecainide) or class 3 (e.g., amiodarone) antiarrhythmic drugs;
15. Subjects who, in the opinion of the investigator, are at significant risk of suicide;
16. Other conditions that the investigator considers unsuitable for enrollment.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Sequential Assignment

Masking: None (Open label)

---

12 participants in 1 patient group

Autologous Human Polyclonal Regulatory T Cells Injection (NP001 Cell Injection)

Experimental group

Description:

Regulatory T cell therapy, intrathecal injection

Treatment:

Biological: Autologous Human Polyclonal Regulatory T Cells Injection (NP001 Cell Injection)